The meta-analysis revealed that three of the four assays most commonly utilized in I/O research, PD-L1 IHC, tumor mutation burden (TMB), and gene expression profiling (GEP), had moderate, comparable performance when predicting response to anti–PD-1/PD-L1 therapy. This evidence concerns the gene CD274 and neoplasm.